Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study

Int J Cardiol. 2015 Feb 1:180:122-8. doi: 10.1016/j.ijcard.2014.11.181. Epub 2014 Nov 26.

Abstract

Background: An elevated resting heart rate (RHR) may be an early sign of cardiac failure, but its prognostic value during watchful waiting in asymptomatic aortic stenosis (AS) is largely unknown.

Methods: RHR was determined by annual ECGs in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study of asymptomatic mild-to-moderate AS patients. Primary endpoint in this substudy was major cardiovascular events (MCEs) and secondary outcomes its individual components. Multivariable Cox-models using serially-measured RHR were used to examine the prognostic impact of RHR per se.

Results: 1563 patients were followed for a mean of 4.3years (6751 patient-years of follow-up), 553 (35%) MCEs occurred, 10% (n=151) died, including 75 cardiovascular deaths. In multivariable analysis, baseline RHR was independently associated with MCEs (HR 1.1 per 10min(-1) faster, 95% CI: 1.0-1.3) and cardiovascular mortality (HR 1.3 per 10min(-1) faster, 95% CI: 1.0-1.7, both p≤0.03). Updating RHR with annual in-study reexaminations, time-varying RHR was highly associated with excess MCEs (HR 1.1 per 10min(-1) faster, 95% CI: 1.1-1.3) and cardiovascular mortality (HR 1.4 per 10min(-1) faster, 95% CI: 1.2-1.7, both p≤0.006). The association of RHR with MCEs and cardiovascular mortality was not dependent on atrial fibrillation status (both p≥0.06 for interaction).

Conclusions: RHR is independently associated with MCEs and cardiovascular death in asymptomatic AS (Clinicaltrials.gov; unique identifier NCT00092677).

Keywords: Aortic valve stenosis; Resting heart rate; Risk stratification.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Aortic Valve Stenosis / complications*
  • Aortic Valve Stenosis / drug therapy
  • Aortic Valve Stenosis / physiopathology
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / physiopathology*
  • Azetidines / therapeutic use*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Ezetimibe
  • Female
  • Follow-Up Studies
  • Global Health
  • Heart Failure / epidemiology
  • Heart Failure / etiology
  • Heart Failure / physiopathology*
  • Heart Rate / physiology*
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Rest / physiology*
  • Simvastatin / therapeutic use*
  • Survival Rate / trends
  • Time Factors

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Simvastatin
  • Ezetimibe

Associated data

  • ClinicalTrials.gov/NCT00092677